UNASSIGNED: To review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination as adjuvant management. This review aims to describe the current state of vaccination programs and demonstrate the long-term protection and safety of vaccines implemented worldwide targeting adolescent girls, with the most recent published evidence of the three prophylactic HPV vaccines - bivalent (bHPV), quadrivalent (qHPV), and nonavalent (nHPV)-. We mainly focus on publications evaluating efficacy, dosing schemes, and HPV vaccination, as well as studies contributing to the mounting evidence for the real-life effectiveness of prophylactic HPV vaccines from several countries.
UNASSIGNED: Human Papillomavirus vaccination programs have made remarkable strides in preventing HPV-related diseases; countries with robust vaccination efforts have witnessed substantial reductions in HPV-related diseases with a decline in high-grade cervical abnormalities and genital warts (54%-83%). However, global coverage remains uneven, with disparities between high-income (HICs) and low-income countries (LMICs). The long-term efficacy of the available human papillomavirus (HPV) goes up to 9.4 years and continues to be immunogenic and well tolerated with an excellent safety profile.
UNASSIGNED: As these are crucial topics in HPV vaccination, it is essential to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time.
■为了回顾有关有效性的文献,长期保护,以及HPV疫苗接种计划和疫苗接种作为辅助管理的安全性。这篇综述旨在描述疫苗接种计划的现状,并展示全球范围内针对少女实施的疫苗的长期保护和安全性。与最近发表的三种预防性HPV疫苗的证据-二价(bHPV),四价(qHPV),和非单价(nHPV)-。我们主要关注评估疗效的出版物,给药方案,和HPV疫苗接种,以及来自多个国家的预防性HPV疫苗在现实生活中的有效性越来越多的证据的研究。
人乳头瘤病毒疫苗接种计划在预防HPV相关疾病方面取得了显著进展;疫苗接种力度较大的国家已经见证了HPV相关疾病的大幅减少,高度宫颈异常和生殖器疣的减少(54%-83%)。然而,全球覆盖面仍然不均衡,高收入国家(HIC)和低收入国家(LMIC)之间的差距。可用的人乳头瘤病毒(HPV)的长期疗效高达9.4年,并继续具有免疫原性和良好的耐受性,具有出色的安全性。
■由于这些是HPV疫苗接种的重要主题,建立持续监测疫苗免疫原性的系统至关重要,功效,和安全随着时间的推移。